SEP
TEVA icon

Signature Equity Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Signature Equity Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.5K Buy
458
+374
+445% +$12.5K 0.01% 721
2026
Q1 		$2.53K Sell
84
-351
-81% -$11.3K ﹤0.01% 1077
2025
Q4 		$13.6K Buy
+435
New +$10.7K 0.01% 757

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Signature Equity Partners's TEVA Position: Q2 2026 in Review

Signature Equity Partners increased its Teva Pharmaceuticals (TEVA) stake by 445% in Q2 2026, buying an estimated $12.5K and bringing the position to 458 shares worth $15.5K. The position accounts for 0.01% of the portfolio, ranked #721.

Signature Equity Partners first reported a position in TEVA in Q4 2025 and has held it in 3 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Signature Equity Partners held 458 shares of Teva Pharmaceuticals worth $15.5K as of Q2 2026.
  • Signature Equity Partners bought 374 Teva Pharmaceuticals shares in Q2 2026, an estimated $12.5K.
  • Teva Pharmaceuticals made up 0.01% of Signature Equity Partners's portfolio in Q2 2026, its #721 holding.
  • Signature Equity Partners first reported a position in Teva Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.